The relationship between serum levels of LOX-1, hs-cTnT, NGAL, and renal function, and their diagnostic value in patients with chronic kidney disease: a retrospective study.

Background: The primary aim of this study is to explore the relationship between serum levels of LOX-1, hs-cTnT, and NGAL, and renal function in patients with CKD, as well as to evaluate their diagnostic value for early detection and monitoring of disease progression in CKD patients.

Methods: A retrospective study was conducted on 108 patients with chronic kidney disease admitted to our hospital from January 2023 to December 2023. The patients were divided into the mild renal insufficiency group (51 cases) and the severe renal insufficiency group (57 cases).

A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLAR-associated membranous nephropathy.

Objective: To evaluate the efficacy and safety of hydroxychloroquine sulfate (HCQ) in the treatment of low risk phospholipase A receptor (PLAR)-associated membranous nephropathy (MN).

Methods: A total of 110 patients with low risk PLAR-associated MN were included in the study. Patients who met the inclusion and exclusion criteria were assigned randomly to two groups: the HCQ treatment group and the control group.

Efficacy and safety of dual renin-angiotensin system (RAS) blockade for non-elderly diabetic kidney disease patients with preserved eGFR.

Aim: Although sodium glucose cotransporter2 inhibitor (SGLT-2I) is widely used in clinical practice, sufficient renin-angiotensin system (RAS) inhibition remains the cornerstone of diabetic kidney disease (DKD) treatment. The aim of this single-center study was to evaluate the efficacy and safety of dual RAS blockade compared with angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) monotherapy in non-elderly DKD patients with preserved eGFR (WHO Standard, < 60y).

Methods: This single-center study was registered in Chinese Clinical Trial Registry (ChiCTR1900024752), and approved by the ethical committee (KY201994).

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus.

Consistent evidence is still lacking on which one, glimepiride plus metformin or repaglinide plus metformin, is better in treating type 2 diabetes mellitus (T2DM). Therefore, this study was conducted to compare the short-term efficacy and safety of these two methods in treating T2DM. The literature research dating up to August 2018 was conducted in the electronic databases.

Treatment of pretibial myxedema with intralesional immunomodulating therapy.

Objective: Local immune regulation therapy has been one of the therapeutic methods used for the treatment of autoimmune thyroid disease in patients with pretibial myxedema (PTM). However, the poor response rate and high recurrence rate are still major problems. Whether a premixed corticosteroid, compound betamethasone, could enhance remission rate and decrease recurrence rate in patients with PTM was investigated in the present study.

Ghrelin-attenuated cognitive dysfunction in streptozotocin-induced diabetic rats.

Diabetic encephalopathy is clinically characterized by acquired behavior and cognitive dysfunction but its pathogenesis is not clear. This study aimed to explore the pathogenesis of diabetic encephalopathy and the mechanisms of ghrelin to ameliorate cognitive dysfunction in diabetic rats. Thirty-six streptozotocin diabetic rat models were established; 12 weeks later, all the rats were randomly divided into 3 groups [diabetic model group (D), ghrelin treatment group (T1), and ghrelin and D-lys-3-GHRP-6 treatment group (T2)] of 12 each.